Journal of Thrombosis and Thrombolysis

, Volume 23, Issue 2, pp 93–100 | Cite as

Heparin resistance in acute coronary syndromes

  • Jonathan D. Rich
  • John M. Maraganore
  • Edward Young
  • Rosa-Maria Lidon
  • Burt Adelman
  • Paul Bourdon
  • Supoat Charenkavanich
  • Jack Hirsh
  • Pierre Theroux
  • Christopher P. Cannon
Article

Abstract

Background

Maintaining a therapeutic level of anticoagulation with unfractionated heparin remains a major challenge for clinicians because of the wide variability of patient responses, which may be explained by variable binding of heparin to plasma proteins. Direct thrombin inhibitors may offer an advantage in more predictable anticoagulation.

Methods

Plasma samples from normal volunteers, stable coronary artery disease (CAD) patients, unstable angina patients, and acute myocardial infarction patients were obtained. A fixed concentration of heparin (.13 U/ml) or bivalirudin (1.6 μg/ml) was added to plasma from each of the four study groups and measurement of the APTT was performed. In addition, a pool of plasma from patients with acute MI was diluted in pooled normal plasma, and heparin or bivalirudin was added to the plasma preparation and APTT measurements performed.

Results

In heparin-treated plasma samples, mean APTT values were 443 ± 137% baseline for normal volunteers, 347 ± 116% for patients with stable CAD, 290 ± 124% for patients with unstable angina (p < 0.05), and 230 ± 120% for patients with acute MI (p < 0.05). APTT did not differ across the four groups treated with bivalirudin. There was a much higher degree of variability in APTT values in heparin treated controls (272%–671%, SD ∼30%) compared to bivalirudin treated controls (284–499%, SD ∼12%). When the “acute MI pool” was diluted in pooled normal plasma at fixed concentrations of either bivalirudin (1.6 μg/ml) or heparin (0.13 U/ml), there was a sharp decrease in heparin activity from 407% baseline (at 0% acute MI pool) to values as low as 126% baseline (at 100% acute MI pool). A markedly different pattern was seen in the bivalirudin treated samples, where a trend towards decreased APTT values was seen only at the 100% acute MI pool.

Conclusion

Both heparin variability and resistance may limit optimal antithrombotic therapy with heparin in patients with ACS and constitutes a potential advantage of direct antithrombin blockade with bivalirudin.

Keywords

Anticoagulation Heparin Resistance 

References

  1. 1.
    Hirsh J (1991) Heparin. The New England J Med 324(22):1565–1574CrossRefGoogle Scholar
  2. 2.
    Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostasis 67(6):639–643Google Scholar
  3. 3.
    Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 suppl):311S–337SPubMedCrossRefGoogle Scholar
  4. 4.
    Horne MK 3rd, Hutchison KJ (1998) Simultaneous binding of heparin and platelet factor–4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 58(1):24–30PubMedCrossRefGoogle Scholar
  5. 5.
    Young E, Wells P, Holloway S, Weitz J, Hirsh J (1994) Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thrombosis Haemostasis 71(3):300–304Google Scholar
  6. 6.
    Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England J Med 354(14):1477–1488CrossRefGoogle Scholar
  7. 7.
    Antman EM (1996) Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 94(5):911–921PubMedGoogle Scholar
  8. 8.
    Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E et al (1993) Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 71(10):778–782PubMedCrossRefGoogle Scholar
  9. 9.
    Ferguson JJ (1995) Recent advances in the treatment of acute myocardial infarction. Texas Heart Inst J/Texas Heart Inst St 22(1):26–32Google Scholar
  10. 10.
    Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J (1993) Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemostasis 69(2):157–163Google Scholar
  11. 11.
    Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW 2nd (1990) Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29(30):7095–7101PubMedCrossRefGoogle Scholar
  12. 12.
    A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators. The New England J Med 335(11):775–782 (1996)Google Scholar
  13. 13.
    Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The New England J Med 354(14):1464–1476CrossRefGoogle Scholar
  14. 14.
    Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood 79(1):1–17PubMedGoogle Scholar
  15. 15.
    Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. The New England J Med 332(20):1330–1335CrossRefGoogle Scholar
  16. 16.
    Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. The New England J Med 353(10):1028–1040CrossRefGoogle Scholar
  17. 17.
    Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arteriosclerosis Thromb Vascular Biol 17(8):1568–1574Google Scholar
  18. 18.
    Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinay P (1981) The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 197(3):599–609PubMedGoogle Scholar
  19. 19.
    Teien AN, Lie M (1977) Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 10(3):399–410PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenberg RD (1989) Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 87(3B):2S–9SPubMedCrossRefGoogle Scholar
  21. 21.
    Hirsh J, Anand SS, Halperin JL, Fuster V (2001) Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association. Circulation 103(24):2994–3018PubMedGoogle Scholar
  22. 22.
    McGarry TF Jr, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH (1992) The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 123(6):1445–1451PubMedCrossRefGoogle Scholar
  23. 23.
    Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Int Med 154(1):49–56CrossRefGoogle Scholar
  24. 24.
    Becker RC, Ball SP, Eisenberg P, Borzak S, Held AC, Spencer F, Voyce SJ, Jesse R, Hendel R, Ma Y, Hurley T, Hebert J (1999) A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J 137(1):59–71PubMedCrossRefGoogle Scholar
  25. 25.
    Hochman JS, Wali AU, Gavrila D, Sim MJ, Malhotra S, Palazzo AM, De La Fuente B (1999) A new regimen for heparin use in acute coronary syndromes. Am Heart J 138(2 Pt 1):313–318PubMedGoogle Scholar
  26. 26.
    Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJ, Cohen AF (1992) Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86(5):1370–1375PubMedGoogle Scholar
  27. 27.
    Olson ST, Shore JD (1982) Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 257(24):14891–14895PubMedGoogle Scholar
  28. 28.
    Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218(3):725–732PubMedGoogle Scholar
  29. 29.
    Cloyd GM, D’Ambra MN, Akins CW (1987) Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. The J Thoracic Cardiovas Surgery 94(4):535–538Google Scholar
  30. 30.
    Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC (1983) Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. The J Thoracic Cardiovas Surgery 85(3):346–353Google Scholar
  31. 31.
    Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL (1994) Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. The Ann Thoracic Surgery 57(5):1211–1216CrossRefGoogle Scholar
  32. 32.
    Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB (2002) Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global use of strategies to open occluded coronary arteries. Am Heart J 144(1):73–80PubMedCrossRefGoogle Scholar
  33. 33.
    International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97(24):2386–2395 (1998)Google Scholar
  34. 34.
    Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB, Simes RJ, Davis CG, Topol EJ, Califf RM, Moliterno DJ (2002) An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis 14(1):33–42PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Jonathan D. Rich
    • 1
  • John M. Maraganore
    • 2
  • Edward Young
    • 3
  • Rosa-Maria Lidon
    • 4
  • Burt Adelman
    • 2
  • Paul Bourdon
    • 2
  • Supoat Charenkavanich
    • 2
  • Jack Hirsh
    • 5
  • Pierre Theroux
    • 4
  • Christopher P. Cannon
    • 1
  1. 1.TIMI Study Group, Cardiovascular DivisionBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Medical Research, Biogen, Inc.CambridgeUSA
  3. 3.Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada
  4. 4.Division of CardiologyMontreal Heart InstituteMontrealCanada
  5. 5.Department of MedicineMcMaster UniversityHamiltonCanada

Personalised recommendations